IRADIMED CORPORATION Named to Fortune’s 100 Fastest Growing Companies List for 2024
IRADIMED (NASDAQ: IRMD) has been named to Fortune's 100 Fastest Growing Companies list for 2024, ranking 61st. The company, which specializes in non-magnetic MRI-compatible medical devices, earned this recognition based on growth in revenue, profits, and stock returns.
To qualify, companies needed a minimum market cap of $225 million, stock price of at least $5, minimum revenue of $50 million, net income of $10 million, and 20% annual growth in revenue and earnings per share over three years. The ranking considers revenue growth rate, EPS growth rate, and three-year annualized total return through June 28, 2024.
IRADIMED (NASDAQ: IRMD) è stata inserita nella lista delle 100 aziende in più rapida crescita di Fortune per il 2024, classificandosi al 61° posto. L'azienda, specializzata in dispositivi medici compatibili con la risonanza magnetica non magnetici, ha ottenuto questo riconoscimento grazie alla crescita di ricavi, profitti e rendimenti azionari.
Per qualificarsi, le aziende dovevano avere una capitalizzazione di mercato minima di 225 milioni di dollari, un prezzo delle azioni di almeno 5 dollari, ricavi minimi di 50 milioni di dollari, un reddito netto di 10 milioni di dollari e una crescita annuale del 20% in ricavi e utili per azione negli ultimi tre anni. La classifica considera il tasso di crescita dei ricavi, il tasso di crescita degli utili per azione e il rendimento totale annualizzato su tre anni fino al 28 giugno 2024.
IRADIMED (NASDAQ: IRMD) ha sido incluida en la lista de las 100 empresas de más rápido crecimiento de Fortune para 2024, ocupando el puesto 61. La empresa, que se especializa en dispositivos médicos compatibles con resonancia magnética y no magnéticos, ganó este reconocimiento por su crecimiento en ingresos, beneficios y rendimientos de acciones.
Para calificar, las empresas necesitaban una capitalización de mercado mínima de 225 millones de dólares, un precio de acción de al menos 5 dólares, ingresos mínimos de 50 millones de dólares, un ingreso neto de 10 millones de dólares y un crecimiento anual del 20% en ingresos y ganancias por acción durante tres años. La clasificación considera la tasa de crecimiento de ingresos, la tasa de crecimiento de ganancias por acción y el rendimiento total anualizado de tres años hasta el 28 de junio de 2024.
IRADIMED (NASDAQ: IRMD)는 2024년 포춘 100대 가장 빠르게 성장하는 기업 리스트에 들어 61위로 선정되었습니다. 비자기성 MRI 호환 의료 기기를 전문으로 하는 이 회사는 수익, 이익 및 주식 수익의 성장에 기반하여 이 인정을 받았습니다.
자격을 갖추기 위해서는 기업이 최소 2억 2500만 달러의 시가 총액, 최소 5달러의 주가, 최소 5000만 달러의 수익, 1000만 달러의 순이익 및 3년 시간에 걸쳐 매출 및 주당순익(earnings per share) 연 20% 이상 성장해야 했습니다. 이 순위는 수익 성장률, EPS 성장률 및 2024년 6월 28일까지의 3년간 연환산 총 수익률을 고려합니다.
IRADIMED (NASDAQ: IRMD) a été inscrit sur la liste des 100 entreprises à la croissance la plus rapide de Fortune pour 2024, se classant au 61e rang. L'entreprise, spécialisée dans les dispositifs médicaux compatibles avec l'IRM et non magnétiques, a obtenu cette reconnaissance grâce à sa croissance en revenus, bénéfices et rendements boursiers.
Pour se qualifier, les entreprises devaient avoir une capitalisation boursière minimale de 225 millions de dollars, un prix d'action d'au moins 5 dollars, un revenu minimum de 50 millions de dollars, un revenu net de 10 millions de dollars, ainsi qu'une croissance annuelle de 20 % des revenus et des bénéfices par action sur trois ans. Le classement prend en compte le taux de croissance des revenus, le taux de croissance des bénéfices par action et le rendement total annualisé sur trois ans jusqu'au 28 juin 2024.
IRADIMED (NASDAQ: IRMD) wurde in die Liste der 100 am schnellsten wachsenden Unternehmen von Fortune für 2024 aufgenommen und belegt den 61. Platz. Das Unternehmen, das sich auf nicht-magnetische, MRI-kompatible medizinische Geräte spezialisiert hat, erhielt diese Auszeichnung aufgrund von Wachstum bei Umsatz, Gewinnen und Aktienrenditen.
Um sich zu qualifizieren, mussten Unternehmen eine Mindestmarktkapitalisierung von 225 Millionen Dollar, einen Aktienkurs von mindestens 5 Dollar, Mindestumsätze von 50 Millionen Dollar, einen Nettogewinn von 10 Millionen Dollar sowie ein jährliches Wachstum von 20 % bei Umsatz und Gewinn pro Aktie über drei Jahre vorweisen. Die Rangliste berücksichtigt die Umsatzwachstumsrate, die EPS-Wachstumsrate und die annualisierte Gesamtverzinsung über drei Jahre bis zum 28. Juni 2024.
- None.
- None.
WINTER SPRINGS, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance imaging (“MRI”) medical devices and the only provider of a non-magnetic intravenous (“IV”) infusion pump system, and non-magnetic patient vital signs monitoring systems that are designed for use during MRI procedures.
“Being recognized by Fortune as one of the 100 Fastest Growing Companies for 2024 is a tremendous honor,” said Roger Susi, President and Chief Executive Officer of the Company. “This achievement underscores our team’s passion and dedication on delivering innovative medical equipment and value-add to our customers to improve the quality of care. As we continue executing our strategic plan, we are excited to build on this momentum and advance our mission to improve patient safety and drive impactful growth for long-term success.”
IRadimed was ranked 61st on the list, which ranks companies based on growth in revenue, profits, and stock returns. To qualify, a company–domestic or foreign–must be trading on a major U.S. stock exchange; report data in U.S. dollars; file quarterly reports with the SEC; have a minimum market capitalization of
To learn more about Fortune’s 2024 100 Fastest-Growing Companies list, visit fortune.com/100-fastest-growing-companies/2024. All registered trademarks are the property of their respective owners.
About IRADIMED CORPORATION
IRADIMED CORPORATION is a leader in developing innovative Magnetic Resonance Imaging (“MRI”) compatible medical devices. We design, manufacture, market, and distribute MRI-compatible medical devices, accessories, disposables, and related services.
We are the only known provider of a non-magnetic intravenous (“IV”) infusion pump system specifically designed to be safe for use during MRI procedures. We were the first to develop an infusion delivery system circumventing the many dangers and hazards during MRI procedures. Standard infusion pumps contain magnetic and electronic components that can create radio frequency interference and are dangerous to locate in the presence of the powerful magnet that drives an MRI system. Our patented MRidium® MRI compatible IV infusion pump system has a non-magnetic ultrasonic motor, uniquely designed non-ferrous parts, and other special features to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe, and dependable fluid delivery before, during, and after an MRI scan, which is essential to critically ill patients who cannot be removed from their vital medications and children and infants who must generally be sedated to remain immobile during an MRI scan.
Our 3880 MRI-compatible patient vital signs monitoring system has been designed with non-magnetic components and other special features to safely and accurately monitor a patient’s vital signs during various MRI procedures. The Iradimed 3880 system operates dependably in magnetic fields up to 30,000 gauss, which means it can operate virtually anywhere in the MRI scanner room. The Iradimed 3880 has a compact, lightweight design, allowing it to travel with the patient from their critical care unit to the MRI and back, resulting in increased patient safety through uninterrupted vital signs monitoring and decreasing the amount of time critically ill patients are away from critical care units. The features of the Iradimed 3880 include wireless ECG with dynamic gradient filtering; wireless SpO2 using Masimo® algorithms; non-magnetic respiratory CO2; invasive and non-invasive blood pressure; patient temperature, and optional advanced multi-gas anesthetic agent unit featuring continuous Minimum Alveolar Concentration measurements. The Iradimed 3880 MRI-compatible patient vital signs monitoring system has an easy-to-use design and effectively communicates patient vital signs information to clinicians.
For more information, please visit www.iradimed.com.
Media Contact:
Jack Glenn
IRADIMED CORPORATION
(407) 677-8022
InvestorRelations@iradimed.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/19884285-baa5-4712-9a17-e684d2a1632f
FAQ
What rank did IRMD achieve on Fortune's 100 Fastest Growing Companies list for 2024?
What were the qualification criteria for Fortune's 2024 fastest-growing companies list?
What type of medical devices does IRMD specialize in?
How does Fortune determine the rankings for its 100 Fastest Growing Companies list?
